Navigation Links
Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema

BASEL, Switzerland, April 25, 2007 - Basilea Pharmaceutica Ltd. (SWX:BSLN) reported today phase III study results showing that patients with severe chronic hand eczema can benefit from re-treatment with alitretinoin. In two previous randomized clinical trials, alitretinoin was found to be effective in treating severe chronic hand eczema in patients refractory to topical treatments. This pivotal trial demonstrated that patients responsive to initial treatment with alitretinoin can also benefit from additional treatment courses after eventual disease recurrence. The safety profile of alitretinoin observed in this study was consistent with that seen in previous trials. These positive data will be integrated into regulatory submissions planned for later this year.

Severe refractory Chronic Hand Eczema (CHE) is a relapsing disorder for which no approved treatment currently exists. This debilitating disease prevents patients from using their hands normally and requires frequent treatment interventions over time.

The objective of this re-treatment study was to describe the safety and efficacy of a second treatment course of alitretinoin in patients who achieved clear or almost clear hands after a previous initial treatment course. This study included 117 patients who eventually had disease recurrence, and 243 patients who had incomplete response after the initial treatment trial.

Patients who had disease recurrence were randomized in double blind manner to receive another 12 to 24 weeks treatment with either placebo or their previous dose of alitretinoin. Response rates were 80% for the alitretinoin 30mg group (Placebo 8.3%) and 48% for the 10mg group (Placebo 10%). These results indicate that alitretinoin is effective in treating severe refractory CHE in subsequent treatment courses.

Those patients who had either no or an incomplete response in the previous study received 30mg alitretinoin
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
2. Scientific Results Presented At ECCMID Demonstrate Well- Differentiated Profile of Basileas Two Phase III Anti- infective Compounds
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine

Post Your Comments:
(Date:12/2/2009)... 2 Keryx Biopharmaceutic...e U.S. Food and Drug Administration (FDA) has gran...e), the Company,s novel, potentially first-in-clas...oinositide 3-kinase (PI3K)/Akt pathway, for the tr... ,, The Fast Track program of the FDA is design...
(Date:12/2/2009)...., Dec. 2 Roche (SIX: RO...ed States Food & Drug Administration (FDA) app...nucleic acid test, to screen source plasma in pool...test, called the cobas® TaqScreen MPX Test fo...e, in-vitro test for the simultaneous, direct dete...
(Date:12/2/2009)...ember 2 Amsterdam Molecu...field of human gene therapy,announced today a num...as,been appointed Chief Financial Officer, effecti... Director Process Development & Manufacturing,...d Project Management, also,effective December 1. T...
Breaking Medicine Technology:Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 2Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 3Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 4FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3AMT Announces Management Changes in Light of Refocused Strategy 2AMT Announces Management Changes in Light of Refocused Strategy 3Radius Investigational Bone Anabolic Agent BA058 Increased Bone Mineral Density 28BMD 29 at Key Fracture Sites in Phase 2 Clinical Trial in Postmen 4829 1Radius Investigational Bone Anabolic Agent BA058 Increased Bone Mineral Density 28BMD 29 at Key Fracture Sites in Phase 2 Clinical Trial in Postmen 4829 2Radius Investigational Bone Anabolic Agent BA058 Increased Bone Mineral Density 28BMD 29 at Key Fracture Sites in Phase 2 Clinical Trial in Postmen 4829 3Radius Investigational Bone Anabolic Agent BA058 Increased Bone Mineral Density 28BMD 29 at Key Fracture Sites in Phase 2 Clinical Trial in Postmen 4829 4SimplyAgeless Believes Michael Jackson Could Have Been Going Through Male Menopause 53710 1SimplyAgeless Believes Michael Jackson Could Have Been Going Through Male Menopause 53710 2Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results 13380 1Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results 13380 2Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results 13380 3Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results 13380 4Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results 13380 5Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results 13380 6
(Date:12/2/2009)... , Ruling by federal government ends nine mont...ELES, Dec. 2 More than ... Permanente facilities across Southern California ...ional Union of Healthcare Workers (NUHW). ,, A ...HW in February, but SEIU delayed the election by f...
(Date:12/2/2009)...Calif.Researchers from the California Institute of...tail, and for the first time, the previously myste...lled ubiquitin are added by enzymes called ubiquit.... Ubiquitin chains tag target proteins for destruc..., "We found that ubiquitin ligases build ubiquiti...
(Date:12/2/2009)...cer patients who have a prostate-specific antigen ...ars after external beam radiation therapy (EBRT) a...cer-related death, according to a study in the Dec...ation Oncology*Biology*Physics, the official journ...(ASTRO)., PSA levels in a prostate cancer patien...
(Date:12/2/2009)...VA Constraint-induced movement therapy (CIMT) is ...hildren with hemiplegic cerebral palsy, but more r...eview published in the November issue of Physical...rican Physical Therapy Association (APTA). The rev...systematic reviews, concluded that further researc...
(Date:12/2/2009)... AB First Aid has been a top name in th...1980. With quality products, professional staff, a...supplies, AB First Aid has established itself as a...ce care, and as a first aid supplies distributor. ...is about to enter into its next phase with the red...
Breaking Medicine News(10 mins):Health News:Labor Board OKs 2,300 Kaiser Professionals to Quit SEIU and Join National Union of Healthcare Workers 2Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 2Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 3Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 4Health News:PSA value at 2 years post-treatment can predict long-term survival in prostate cancer patients 2Health News:Report shows CIMT may improve arm use in children with hemiplegic cerebral palsy 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 2Health News:From A to B and Everything In-between; AB First Aid Launch New Web Storefront 3
...is suggested that the fat cells around coronary ar...searchers from the University of Iowa have found... inflammation. Which under certain circumstances, ...art disease, presented their findings to the Exper...
...ays that children's habits are largely determined ...ning if a child would be an avid reader. // “Ch...lded,” said Phillip Dale, professor and chair of t...mponent.” The study used data from more than 6,000...
...ld be trained in the diagnosis and primary treatme...ect, to be conducted by the IMA’s medical specialt...ancial assistance to the project. A memorandum...t has been observed that doctors often shy away fr...
...et helps you to have fewer wrinkles thereby making... People with a normal diet can make their skin ... paprika in their meals, German magazine The Derma...xidants contained in the body stop free-radical da...
...se of light and vitamin B2, promises to be an eye .... // It is well known that almost 10,000 Australia...ed keratoconus, which can ultimately lead to blind...VA light to fall on the eye, which will strengthen...
...and drug resistant and added to this seem to bespr... deadly health menace, according to a warning issu...present in large hospitals for a good many years, ...ny contact with hospitals. Lead researcher a...
Other Medicine News:Health News:Fat Cells Can Trigger Heart Diseases 2Health News:IMA To Train Doctors In Primary Treatment Of HIV/AIDS 2Health News:Golden Staph- the super bug spreads, posing a major health risk. 2
STAARVISC II
...igned with optimum molecular weight and viscosity,...ts and protects the delicate structures of the eye..., adhesion, and pseudoplasticity to satisfy all th...ts from an ophthalmic viscoelastic device. , ,...
...m Hyaluronate (1.8%) viscoelastic solution combine...use. Rayflo maintains a deep anterior chamber and ...y. It is ideal for routine cataract surgery but ca...a viscoelastic. Combine all these properties with ...
...terile, non-pyrogenic, transparent viscoelastic pr...igh molecular weight (average molecular weight 4 m... mg/mL of sodium hyaluronate 5000, dissolved in re...and sodium glucuronate linked by glycosidic bonds....
Medicine Products: